Fig. 2.

Median cost per HCC prevented over 10 years in Asian countries (USD in thousands). ETV had the lowest cost per HCC saved for full paying patients (US$1 million). However, there is no reimbursement for ETV in most Asian countries, consequently ADV/LMV and LMV/ADV strategies are cheaper from patients’ perspective after reimbursement, as patients would have to pay the full cost for ETV. Median cost taken from survey on various Asian countries (Table 1). Subsidized cost = cost to patient after reimbursement, ETV = entecavir, ADV = adefovir, LMV = lamivudine, USD = United States dollars